| The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. | None |
| [Proto-oncogene c-src regulates the viability of rat spermatogonial stem cells in vitro through phosphorylated signal transducer and activator of transcription-3]. | None |
| Global impact of oncogenic Src on a phosphotyrosine proteome. | None |
| v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. | None |
| The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes. | None |
| Effects of transformation with the v-src oncogene on inositol phosphate metabolism in rat-1 fibroblasts. D-myo-inositol 1,4,5,6-tetrakisphosphate is increased in v-src-transformed rat-1 fibroblasts and can be synthesized from D-myo-inositol 1,3,4-trisphosphate in cytosolic extracts. | None |
| Differential regulation of glucose transporter isoforms by the src oncogene in chicken embryo fibroblasts. | None |
| The oncogenic activity of the Src family kinase Hck requires the cooperative action of the plasma membrane- and lysosome-associated isoforms. | None |
| Oncogenic potential of c-Src tyrosine kinase is controled by lipid rafts. (review) | None |
| [Lipid rafts controls the oncogenic potential of c-Src]. | None |
| An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. | None |
| The findings presented in this study show that mutant EGFRs undergo aberrant traffic into the endocytic recycling compartment which allows mutant EGFRs to engage in a preferential interaction with Src, a critical partner for EGFR-mediated oncogenesis. | None |
| Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. | None |
| a novel regulatory mechanism of c-Src synthesis mediated by an IRES element, which exhibits enhanced activity during cellular stress and is likely to cause c-Src overexpression during oncogenesis and metastasis. | None |
| Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). | None |
| MRTF-A/B suppress the oncogenic properties of v-ras- and v-src-mediated transformants. | None |
| Neurite extension and protein tyrosine phosphorylation elicited by inducible expression of the v-src oncogene in a PC12 cell line. | None |
| Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation. | None |
| Inhibition of epidermal growth factor receptor biosynthesis caused by the src oncogene product, pp60v-src. | None |
| Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src. | None |